INSP · Inspire Medical Systems, Inc.

Track INSP — free

$63.07 +1.55 (+2.52%) At close · Sep 2

S&P 600 member Russell 2000 member Rebalance outlook locked

Market Cap

$1.78B

28.91M

Up next

Next earnings call

Nov 2, 2026 Est · unconfirmed · in 9 wks

Latest filing: 10-Q

filed Aug 3, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 114 metrics

Revenue (TTM)

$898.74M

Trailing 12 months

Net income (TTM)

$135.04M

Trailing 12 months

Revenue growth YoY

-7.6%

Year over year

Operating margin

6.0%

Trailing 12 months

P / E (TTM)

13.6

Trailing earnings · reciprocal yield 7.4%

FCF yield

6.6%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

-1.9%

Year over year · fewer shares

Price change (1Y)

-34.3%

Trailing year

Short interest

15.1%

Latest settlement · 5.2 days to cover

View all 114 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Neutral Momentum Weak Sentiment Bearish Fundamentals Excellent Quant / Vol Very High

Market backdrop VIX 15.2 · calm Equity put/call 0.56

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg −8%

below

Price vs 50-day avg +14%

above

RSI (14) 60

neutral

MACD trend Negative

52-week position 21%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return −4%

trailing

6-month return +3%

trailing

YTD return −33%

this year

Relative strength −10%

vs S&P · 6-mo

Sentiment

smart money

Bearish

Trend (MA cross) No cross

50d $54 › 200d $67 — 200d above 50d

Institutional flow Distributing

-9% holders QoQ · +69 funds added

Insider flow Distributing

Net -$57.3K over 90 days · 100% sells

Short interest Rising

15.13% of float · ▲ +11.6% MoM · 5.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr low

277 holders — near 3-yr low, contrarian setup

Squeeze score 83

high risk · 0–100

Fundamentals

Excellent

Revenue growth +62%

Y/Y

Gross margin 949%

contracting

EPS growth +179%

Y/Y

Free cash flow $78.5M

Valuation P/E 13.6

below peers

Buyback $100.0M

remaining

Balance sheet $190.0M

net cash

Quant / Vol

risk profile

Very High

Volatility 71%

annualized · 1-yr

Max drawdown −72%

past year

ATR 4.1%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

2 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−8% Bearish

Price vs 50-day avg

+14% Bullish

RSI (14)

60 Neutral

MACD trend

Negative Bearish

52-week position

21% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bearish · 3 of 6

Trend (MA cross) No cross

50d $54 › 200d $67 — 200d above 50d

Institutional flow Distributing

-9% holders QoQ · +69 funds added

Insider flow Distributing

Net -$57.3K over 90 days · 100% sells

Short interest Rising

15.13% of float · ▲ +11.6% MoM · 5.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr low

277 holders — near 3-yr low, contrarian setup

Price context

position in its 52-week range

Range low $40 Now $62 · 21% Range high $144

vs 200-day avg -8% vs 50-day avg +14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Medical Devices — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
INSP Inspire Medical Systems, Inc. this stock	$1.78B	-33.3%	+62.2%	13.6	15.1%
ABT Abbott Laboratories	$192.64B	-11.8%	+5.7%	31.0	1.2%
SYK Stryker Corp	$121.41B	-9.7%	+11.2%	32.8	1.8%
MDT Medtronic plc	$117.82B	-4.2%	+8.4%	24.7	1.1%
BSX Boston Scientific Corp	$70.00B	-49.6%	+12.5%	19.6	1.9%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

277

% held: 128.8%
Net QoQ: +2.0M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

295

View

Short & Settlement

Short Interest Rising

Shares short

4.4M

Days to cover: 5.2d
Change: +453.4K sh

View

Short Volume

Short vol %

49%

As of: Sep 2, 2026

Short Total

View

Fails to Deliver

FTD shares

227

Value: $13.7K
As of: Aug 10, 2026

View

Off-Exchange

Off-exchange %

39.6%

Week of: Jul 27, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$57.3K

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Congressional Trades Sell

Member

Daniel Goldman

Amount: $1.0K–$15.0K
Traded: Apr 10, 2023

View

Financials

Revenue (FY)

$912.0M

Net income (FY): $145.4M
EPS diluted: $4.89

View

Buybacks

Authorized

$200.0M

Remaining: $100.0M

Spent Remaining

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 3, 2026
This year: 12

View

Proposed Sales

Value

$4.0K

Shares: 64
Filed: Aug 24, 2026

View

Earnings & Events

Earnings Calls Upcoming

Next call

Sep 9, 2026

Last call: Aug 3, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
INSP	+0.7%	-4.1%	+2.6%	-2.3%	-33.3%
SPY	-0.5%	-1.2%	+12.6%	-0.7%	+11.7%
vs SPY	+1.3%	-2.8%	-10.1%	-1.6%	-45.0%

Capital returns

Buyback program · as of Jun 30, 2026

Authorized

$200.00M

Spent (derived)

$100.00M

Remaining

$100.00M

Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1609550 CUSIP 457730109 13F (30d) 222 filings 212 filers Visit website Investor relations

INSP · Inspire Medical Systems, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Versus peers

At a glance

Performance

Capital returns